Avadel Pharmaceuticals AVDL

Jump To Section

    $

    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0
    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0
    .
    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0
    +$0.03 (+0.38%)Past DayToday's Volume:
    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0
    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0
    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0
    ,
    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0
    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0
    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0

    Relative Strength Index (RSI)

    - The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. It is typically used to identify overbought or oversold conditions in financial markets.

    - The RSI is calculated using the following formula:

    RSI = 100 - (100 / (1 + RS))

    Where RS is the ratio of the average gains to the average losses over a specified period.

    - The default time period used is 14 days.

    - RSI values range between 0 and 100.

    RSI values above 70 are considered overbought (indicating a potentially opportune time to sell)

    RSI values below 30 are considered oversold (indicating a potentially opportune time to buy)

    RSI is not a perfect indicator and should be used in conjunction with other technical analysis tools, this is for informational purposes only and is not a substitute for professional financial advice.

    About

    Business overview of Avadel Pharmaceuticals (AVDL)
    Avadel Pharmaceuticals PLC is a specialty pharmaceutical company. The group focused on transforming medicines to transform lives. It provides solutions to the development of medications that address the challenges patients face with current treatment options. The company is engaged in the development of differentiated drug products for administration in various forms such as capsules, tablets, injectables etc. Its commercialized product LUMRYZ is an extended-release formulation of sodium oxybate indicated to be taken once at bedtime for the treatment of cataplexy or EDS in adults with narcolepsy. It operates in one segment, the development and commercialization of pharmaceutical products, including controlled-release therapeutic products based on its proprietary polymer-based technology.

    Key Insights

    Critical company metrics and information

    • Latest Closing Price

      $7.91

    • Market Cap

      $764.34 Million

    • Price-Earnings Ratio

      -10.55

    • Total Outstanding Shares

      96.63 Million Shares

    • Total Employees

      188

    • Dividend

      No dividend

    • IPO Date

      June 7, 1996

    • SIC Description

      Pharmaceutical Preparations

    • Primary Exchange

      NASDAQ

    • Type

      Common Stock

    • Headquarters

      Block 10-1 blanchardstown corporate park, Dublin, L2, 15

    • Homepage

      https://www.avadel.com

    Historical Stock Splits

    Execution DateSplit Amount
    No Historical Stock Splits

    Cash Flow Statement

    October 1, 2023 to September 30, 2024
    MetricValue
    Net Cash Flow From Investing Activities, Continuing$64.80 Million
    Net Cash Flow From Operating Activities, Continuing$-82.81 Million
    Net Cash Flow From Financing Activities$-6.02 Million
    Exchange Gains/Losses$806,000
    Net Cash Flow, Continuing$-24.04 Million
    Net Cash Flow From Financing Activities, Continuing$-6.02 Million

    Income Statement

    October 1, 2023 to September 30, 2024
    MetricValue
    Diluted Average Shares$97.96 Million
    Revenues$138.16 Million
    Income/Loss From Continuing Operations Before Tax$-73.00 Million
    Preferred Stock Dividends And Other Adjustments$0
    Research and Development$13.28 Million
    Selling, General, and Administrative Expenses$177.72 Million

    Comprehensive Income

    October 1, 2023 to September 30, 2024
    MetricValue
    Comprehensive Income/Loss Attributable To Parent$-70.43 Million
    Other Comprehensive Income/Loss$-70.43 Million
    Other Comprehensive Income/Loss Attributable To Parent$2.15 Million
    Comprehensive Income/Loss Attributable To Noncontrolling Interest$0
    Comprehensive Income/Loss$-70.43 Million

    Balance Sheet

    October 1, 2023 to September 30, 2024
    MetricValue
    Prepaid Expenses$6.31 Million
    Equity Attributable To Parent$74.66 Million
    Liabilities And Equity$158.25 Million
    Equity Attributable To Noncontrolling Interest$0
    Fixed Assets$469,000
    Accounts Payable$7.92 Million

    Historical Dividends

    Announcement DatePayment DateRecord DateAmountFrequency
    No historical dividends

    Recent Headlines From The Web

    Latest news, press releases, and media coverage about AVDL from trusted financial sources
      Boost your savings and earn 4.15% APY with a Marcus by Goldman Sachs savings account, a rate that's 8x the national averagewhen signing up with Financhle. No fees, no minimum deposits, backed by the financial expertise of Goldman Sachs. Terms apply.
      All TickersEarnings CalendarNews ArticlesAbout UsPrivacy & Cookies Info

      ⓒ 2025 Financhle. All Rights Reserved.